Molecular Formula | C12H9FN2O2
|
Molar Mass | 232.21 |
Solubility | DMSO : 28 mg/mL (120.58 mM) |
Appearance | solid |
Color | White |
Storage Condition | Inert atmosphere,Room Temperature |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
In vitro study | PF-06840003 is a racemic mixture. Its IC50 for human IDO-1, murine IDO-1, and canine IDO-1 were 0.41, 1.5, and 0.59 μm, respectively. PF-06840003 has only very weak activity against hTDO-2, with an IC50 of 140 μm. In cell experiments, PF-06840003 was active in both Hela cells and LPS/infγ-stimulated THP1 cells with IC50 of 1.8 μm and 1.7 μm, respectively. The inhibitory effect of PF-06840003 on CYPs is very weak, and the IC50 of most CYP isoenzymes is greater than 100 μm (except for 2C19,IC50=78 μm). In addition, PF-06840003 had no metabolism-dependent inhibition of the CYP enzymes involved in the assay. |
In vivo study | PF-06840003 in vivo half-life is about 16-19 hours. Its oral bioavailability in mice, rats and dogs was 59%,94% and 19%, respectively. PF-06840003 monotherapy has significant antitumor activity in Pan02, B16 − F10, CT26, MC38, 4T1, and renal cell carcinoma models; In the CT26 model, PF-06840003 and anti-PDL1 mAb have a synergistic effect. PF-06840003 has a good pharmacokinetic profile in vivo with low/moderate clearance in most preclinical animals. In rats, PF-06840003 can penetrate the central nervous system, indicating its potential in brain metastases. |